NCT05231655Recruiting
Ex VIvo DEtermiNed Cancer Therapy
Ex Vivo Multi Drug Screening of Solid Tumours to Determine Personalised Therapy Efficacy and Resistance
Source: ClinicalTrials.gov · Last updated 24 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments. Patients undergoing standard care surgery to excise their tumour, those undergoing a biopsy, or those having a fluid aspirate of a solid tumour with surplus tissue available after diagnostic use will be eligible for this study. The specimen will then be assessed with ex vivo drug screening utilising all standard therapies and therapies that are more novel and in early stages of development. The results of the ex vivo drug screen will be compared to the cancer's actual response to standard care treatments for those that undergo therapy to determine how effective the test is at predicting treatment response.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 31 Jan 2022
- Start date
- 7 Jul 2021
- Primary completion date
- Jan 2026
- Lead sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Diseases
- Head and neck cancer, Kidney cancer, Bladder cancer, Melanoma, Glioblastoma, Childhood cancers, Sarcoma
- NCT number
- NCT05231655
What you commit to
- Study type: Observational
- Planned participants: 600
- From 7 Jul 2021 to the primary completion date, Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a known diagnosis of a blood borne virus (Hepatitis B, Hepatitis C, HIV). (The laboratories where experiments will be conducted do not have the safety facilities to use material containing these pathogens)
- Patients with a current positive COVID-19 infection
Who the study is looking for
- \>16 years of age with a diagnosis of known or suspected solid cancer who will undergo surgery, biopsy, aspirate, or TURBT
- Willing to donate a section fresh tumour tissue from surgery, a TURBT, fluid aspirate, or biopsy surplus to diagnostic use
- Willing to donate a 9ml blood sample
- Able to give written informed consent
- Previously treated patients are eligible if:
- Present with a recurrence of a previously treated tumour. This may be a local or metastatic recurrence
- Have undergone treatment for their cancer, but fail to respond to this and progress
- Have received neoadjuvant therapy for their tumour
- Have undergone chemotherapy, targeted therapy, immunotherapy, hormone therapy and or radiotherapy for a previous tumour
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sheffield Teaching Hospitals NHS Foundation Trust Coordinator of this site? Confirm its status | Sheffield | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.